UNSPSC 51142417: Almotriptan

This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O4XL5SN61. European Medicines Agency schedules Almotriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05350MIG. Almotriptan generally arises in the molecular formula C17H25N3O2S. The term ALMOTRIPTAN is an International Non-Proprietary Name or INN. ALMOTRIPTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule almotriptan under HS 29350090 and SITC 51580. As of Q4 2014, ALMOTRIPTAN remains the US FDA Preferred Term for this commodity. Almotriptan bears US NLM identifiers UMLS ID C0914729 and NCI Concept Code C65224. SMILES: S(=O)(=O)(N1CCCC1)CC1CC2C(CCN(C)C)C[NH]C2CC1.

UNSPSC 51142417 Almotriptan is a Commodity code nominally identifying a specific migraine therapeutic, but recent state and local solicitations tagged under this code show little activity directly matching the pharmaceutical product itself. The code appears in state and local procurement systems for pharmaceutical and medical supply purchasing, but the opportunities posted under it—including emergency naloxone procurement, direct-to-manufacturer prescription program exploration, and multi-state generic pharmaceutical contracting—do not center on almotriptan specifically. State and local governments use this tier of UNSPSC coding to organize pharmaceutical procurement across health departments, county health systems, and cooperative purchasing alliances, but the recent activity reflects broader pharmaceutical sourcing rather than demand concentrated on this single product. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP), suggesting that pharmaceutical Commodity codes in state and local systems often serve as catch-all categories for multi-product health procurement rather than narrowly targeted product lines.

Recent opportunities under this code span Florida, Texas, and a multi-state cooperative region including Minnesota and Oregon. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with response due July 26, 2023—a date that predates the posting. Texas HHS Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription contracting outside traditional pharmacy benefit managers and wholesalers, without a formal response deadline or award value specified. MMCAP, administered by Minnesota's Department of Administration, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026 and contract awards effective July 1, 2026, requiring vendors to work through three authorized wholesalers and accept a 3 percent administrative fee. The code shows limited activity specifically targeting almotriptan; business development professionals evaluating this code should expect broader pharmaceutical procurement opportunities rather than single-product sourcing.